# OnCo record telotristat-ethyl (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/telotristat-ethyl/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "telotristat-ethyl" ;
  schema:name "Telotristat ethyl"@en ;
  schema:alternateName "LX1032"@en, "Telotristat etiprate"@en, "Xermelo" ;
  schema:description "Telotristat ethyl (Xermelo) is a tablet that cuts the serotonin that neuroendocrine tumours pour out, easing the constant diarrhoea of carcinoid syndrome when somatostatin analogue injections are not enough."@en ;
  schema:url <https://onco.cc/drugs/telotristat-ethyl/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Telotristat_ethyl> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=telotristat> ;
  onco:status "approved" ;
  onco:tag "ema-list", "supportive" ;
  onco:modality "Oral tryptophan hydroxylase inhibitor" ;
  onco:approval "US 2017: Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone", "EU 2017: Same (Xermelo)" ;
  onco:related <https://onco.cc/drugs/octreotide-lanreotide/> ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/small-intestinal-net/> ;
  onco:companies <https://onco.cc/companies/tersera-therapeutics/>, <https://onco.cc/companies/serb-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct03790111/>, <https://onco.cc/trials/nct04543955/> .